Application of astaxanthin and composition in preparing medicine for treating glomerular mesangial lesions

A technology of astaxanthin and a composition is applied in the application field of astaxanthin and the composition in the treatment of mesangial disease glomerular medicine, which can solve the problems of serious side effects, accelerate renal failure and the like, and achieve the reduction of proteinuria, Improve the effect of kidney pathological damage

Inactive Publication Date: 2015-12-23
HUBEI ASTA BIOTECH
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For patients with mild to moderate mesangial lesions, the above treatments have a certain curative effect, but for patients with moderate to severe mesangial lesions, the use of immunosuppressants, glucocorticoids, and cytotoxic drugs is not only not beneficial, but a large amount of blind use may cause serious side effects. Even accelerate renal failure, so it is very necessary to develop drugs with low toxicity and good effect to inhibit chronic inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astaxanthin and composition in preparing medicine for treating glomerular mesangial lesions
  • Application of astaxanthin and composition in preparing medicine for treating glomerular mesangial lesions
  • Application of astaxanthin and composition in preparing medicine for treating glomerular mesangial lesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] Attached below Figure 1-3 Specific embodiments of the present invention will be further described.

[0028] 1. Background and research population

[0029] From December 2014 to June 2015, patients with IgA nephropathy who visited the Nephrology Clinic of Peking University People's Hospital were selected for 3 months with stable urine protein and stable renal function, and patients who were not expected to need adjustment of antihypertensive drugs. The selection criteria of the patients were as follows: 1. All had undergone renal biopsy, and the pathological diagnosis was IgA nephropathy; 2. The urine protein quantification was greater than 1g / d 24 hours before the experiment; 3. No adrenal corticosteroid or immunosuppressant treatment was used in the past 3 months. Exclusion criteria: 1. Patients with serum creatinine levels > 420 μmol / L at enrollment; 2. Patients with infection, unstable blood pressure control, and severe cardiopulmonary diseases; 3. Oral antihyperte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of astaxanthin and a composition in preparing medicine for treating glomerular mesangial lesions. The adopted astaxanthin and composition are of an all-trans-isomer-oriented sinistrality structure, and the medicine is in an oral medication dosage form. Oral absorption promoter can be added or not added in the medicine preparation process of the astaxanthin or derivatives. One kind or any several kinds or all of the oral absorption promoter is added, and the any several kinds or all the oral absorption promoter is added according to any proportion. After the medicine is used by an IgA nephritic patient, it is observed that after the astaxanthin and the composition are taken, 24HUP is remarkably reduced, Scr tends to be increased, eGFR tends to be reduced, and the changes of 24HUP, Scr and eGFR all have statistical significance. After the medicine is adopted, AIba and TG are different in overall data, no change trend is found, and no remarkable change of Tchol or HDL-c or LDL-c is observed.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an application of astaxanthin and its composition in the treatment of glomerular mesangial lesions. Background technique [0002] Astaxanthin, also known as "astaxanthin", is a major carotenoid oxidation product in aquatic animals in nature. The chemical name is 3,3-dihydroxy-4,4-hydroxy-β-carotene, and its molecular structure is as follows: [0003] [0004] Astaxanthin is a chain-breaking antioxidant with strong antioxidant capacity and the ability to fight chronic inflammation. Its antioxidant capacity is 550 times that of vitamin E (even animal experiments have shown that it can be as high as 1000 times), and it is 10 times that of natural β-carotene. Animal experiments have shown that astaxanthin can scavenge NO, sulfide, and dioxide, and can also reduce lipid peroxidation, effectively inhibiting lipid peroxidation caused by free radicals. The core mechanism of its anti-infl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61P13/12A61P29/00A61P39/06
Inventor 张邦华商向群左力
Owner HUBEI ASTA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap